e-Therapeutics plc Director/PDMR Shareholding (9843J)

TIDMETX

RNS Number : 9843J

e-Therapeutics plc

03 July 2017

E-THERAPEUTICS PLC

("e-Therapeutics" or the "Company")

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS

DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY

Oxford, UK, 3 July 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that on 3 July 2017 Professor Trevor Jones (Non-Executive Director) subscribed for a total of 45,364 new ordinary shares of 0.1p each in the Company (the "New Ordinary Shares") at a price of 12.125 pence per share. The subscription monies paid for the New Ordinary Shares represent 50% of Professor Jones' Non-Executive Director fees net of tax paid during the period from 1 January 2017 to 30 June 2017.

Application has been made to AIM for the admission of the New Ordinary Shares to trading on AIM ("Admission") and Admission is expected to occur on 10 July 2017. The New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares in issue.

Following Admission, Professor Jones will be interested in a total of 212,261 ordinary shares of 0.1p in the Company, representing approximately 0.08% of the Company's issued share capital.

Following Admission, the total number of ordinary shares in the Company with voting rights in issue will be 268,471,406. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

The Company previously announced that on 5 October 2016 Professor Jones entered into a binding contractual arrangement with the Company under which he agreed, with effect from 1 October 2016, to invest 50% of his annual Non-Executive Director fees net of tax in new e-Therapeutics' ordinary shares.

The new shares will be issued to Professor Jones on the first business day after 31 December and 30 June in each year. The subscription price to be paid will be the average of the closing mid-market price for the five business days prior to the date of issue. The terms pursuant to which Professor Jones will purchase the shares are fixed, and he has irrevocably committed to such terms.

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:

 
 1    Details of the person discharging managerial 
       responsibilities/person closely associated 
---  ------------------------------------------------------------ 
 a)   Name                      Trevor Jones 
---  ------------------------  ---------------------------------- 
 2    Reason for the notification 
---  ------------------------------------------------------------ 
 a)   Position/status           Non-Executive Director 
---  ------------------------  ---------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
---  ------------------------  ---------------------------------- 
 3    Details of the issuer, emission allowance market 
       participant, auction platform, auctioneer or 
       auction monitor 
---  ------------------------------------------------------------ 
 a)   Name                      e-Therapeutics plc 
---  ------------------------  ---------------------------------- 
 b)   LEI                       21380049RHSSJXWKYT18 
---  ------------------------  ---------------------------------- 
 4    Details of the transaction(s): section to be 
       repeated for (i) each type of instrument; (ii) 
       each type of transaction; (iii) each date; and 
       (iv) each place where transactions have been 
       conducted 
---  ------------------------------------------------------------ 
 a)   Description of            Ordinary Shares of 0.1 pence 
       the financial 
       instrument, type          ISIN: GB00B2823H99 
       of instrument 
       Identification 
       code 
---  ------------------------  ---------------------------------- 
 b)   Nature of the             Purchase of shares 
       transaction 
---  ------------------------  ---------------------------------- 
 c)   Price(s) and              45,364 ordinary shares at a price 
       volume(s)                 of 12.125 pence per share 
---  ------------------------  ---------------------------------- 
 d)   Aggregated information    N/A 
       - Aggregated 
       volume 
       - Price 
---  ------------------------  ---------------------------------- 
 e)   Date of the transaction   3 July 2017 
---  ------------------------  ---------------------------------- 
 f)   Place of the              London Stock Exchange, AIM (XLON) 
       transaction 
---  ------------------------  ---------------------------------- 
 

For further information, please contact:

Contacts:

 
 E-Therapeutics plc                 Tel: [phone] 
  Iain Ross, Chairman                883 125 
  Steve Medlicott, CFO               www.etherapeutics.co.uk 
 Numis Securities Limited           Tel: +44 (0) 207 
  Michael Meade/Freddie Barnfield    260 1000 
  (Corporate Finance)                www.numis.com 
  James Black (Corporate 
  Broking) 
 Instinctif Partners                Tel: +44 (0) 207 
  Melanie Toyne Sewell/Alex          457 2020 
  Shaw                               Email: [e-mail] 
 

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHLLFSEDDIVIID

(END) Dow Jones Newswires

July 03, 2017 11:50 ET (15:50 GMT)